Compare HUMA & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUMA | LFCR |
|---|---|---|
| Founded | 2004 | 1986 |
| Country | United States | United States |
| Employees | 184 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 190.9M |
| IPO Year | N/A | 1996 |
| Metric | HUMA | LFCR |
|---|---|---|
| Price | $0.72 | $4.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $6.19 | $6.00 |
| AVG Volume (30 Days) | ★ 5.0M | 135.0K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | $444.16 | N/A |
| Revenue Next Year | $248.39 | $5.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $0.55 | $3.63 |
| 52 Week High | $2.55 | $8.98 |
| Indicator | HUMA | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 53.64 |
| Support Level | $0.63 | $4.63 |
| Resistance Level | $0.87 | $5.27 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 81.13 | 74.20 |
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.